JPWO2020112880A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020112880A5 JPWO2020112880A5 JP2021530816A JP2021530816A JPWO2020112880A5 JP WO2020112880 A5 JPWO2020112880 A5 JP WO2020112880A5 JP 2021530816 A JP2021530816 A JP 2021530816A JP 2021530816 A JP2021530816 A JP 2021530816A JP WO2020112880 A5 JPWO2020112880 A5 JP WO2020112880A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- individual
- period
- compound
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 28
- 239000012453 solvate Substances 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- 102000025380 C-Reactive Protein Human genes 0.000 claims description 10
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 10
- 230000002550 fecal Effects 0.000 claims description 10
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 9
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 7
- 241000349774 Bikinia letestui Species 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 210000004400 Mucous Membrane Anatomy 0.000 claims description 4
- 230000003042 antagnostic Effects 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 201000006704 ulcerative colitis Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims description 2
- 230000001861 immunosuppresant Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 229960004914 vedolizumab Drugs 0.000 claims description 2
- 108010035693 vedolizumab Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 claims 4
- 101710031679 HEXIM1 Proteins 0.000 claims 1
- 102100014085 S1PR1 Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- DUYSYHSSBDVJSM-KRWOKUGFSA-N Sphingosine-1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 8
- 230000004043 responsiveness Effects 0.000 description 8
- -1 hydrate Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773936P | 2018-11-30 | 2018-11-30 | |
| US62/773,936 | 2018-11-30 | ||
| US201962850464P | 2019-05-20 | 2019-05-20 | |
| US62/850,464 | 2019-05-20 | ||
| PCT/US2019/063413 WO2020112880A1 (fr) | 2018-11-30 | 2019-11-26 | Méthodes de traitement d'états liés au récepteur s1p1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511788A JP2022511788A (ja) | 2022-02-01 |
| JPWO2020112880A5 true JPWO2020112880A5 (fr) | 2022-12-05 |
Family
ID=68966033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530816A Pending JP2022511788A (ja) | 2018-11-30 | 2019-11-26 | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220023258A1 (fr) |
| EP (1) | EP3886841A1 (fr) |
| JP (1) | JP2022511788A (fr) |
| KR (1) | KR20210098487A (fr) |
| CN (1) | CN113226307A (fr) |
| AU (1) | AU2019387212A1 (fr) |
| CA (1) | CA3120706A1 (fr) |
| IL (1) | IL283414A (fr) |
| WO (1) | WO2020112880A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103221391B (zh) | 2010-01-27 | 2018-07-06 | 艾尼纳制药公司 | (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法 |
| CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
| US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
| MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
| EP3582772A1 (fr) | 2017-02-16 | 2019-12-25 | Arena Pharmaceuticals, Inc. | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE030424T2 (en) | 2008-07-23 | 2017-05-29 | Arena Pharm Inc | Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| CN103221391B (zh) | 2010-01-27 | 2018-07-06 | 艾尼纳制药公司 | (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法 |
| EP2811832A4 (fr) * | 2012-02-03 | 2015-09-23 | Teva Pharma | Utilisation de laquinimod pour le traitement de patients souffrant de la maladie de crohn pour lesquels la thérapie anti-tnf de première intention a échoué |
| CN107405332A (zh) * | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
-
2019
- 2019-11-26 KR KR1020217019803A patent/KR20210098487A/ko unknown
- 2019-11-26 CN CN201980087042.4A patent/CN113226307A/zh active Pending
- 2019-11-26 JP JP2021530816A patent/JP2022511788A/ja active Pending
- 2019-11-26 CA CA3120706A patent/CA3120706A1/fr active Pending
- 2019-11-26 WO PCT/US2019/063413 patent/WO2020112880A1/fr unknown
- 2019-11-26 AU AU2019387212A patent/AU2019387212A1/en active Pending
- 2019-11-26 EP EP19824097.0A patent/EP3886841A1/fr active Pending
- 2019-11-26 US US17/299,741 patent/US20220023258A1/en active Pending
-
2021
- 2021-05-25 IL IL283414A patent/IL283414A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| US20200323843A1 (en) | Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus | |
| JP2015526458A5 (fr) | ||
| JP2020529996A5 (fr) | ||
| WO2010071866A2 (fr) | Combinaison thérapeutique pour l'arthrite avec du tranilast | |
| JP2019504096A (ja) | サクビトリルおよびバルサルタンの組合せの新規使用 | |
| JP5362151B2 (ja) | Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| WO2012161301A1 (fr) | Agent prophylactique ou thérapeutique pour la douleur neuropathique associée au syndrome de guillain-barré | |
| JPWO2020112880A5 (fr) | ||
| JP4614640B2 (ja) | 解熱剤組成物 | |
| US11666587B2 (en) | Veterinary composition comprising torasemide for the treatment of pulmonary edema associated with heart failure in domestic animals | |
| JP2002523363A (ja) | 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用 | |
| TWI777059B (zh) | 肌肉減少症之預防劑及治療劑 | |
| JP2009535336A (ja) | 片頭痛治療用の固定組合せ剤形 | |
| WO2016006621A1 (fr) | Médicament contenant un antagoniste de pgd2 pour le traitement des symptômes associés aux maladies allergiques | |
| JPWO2020146529A5 (fr) | ||
| CN115702143A (zh) | 治疗系统性硬化症的方法 | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| JPWO2020072824A5 (fr) | ||
| JPWO2021142030A5 (fr) | ||
| RU2021123406A (ru) | Способы лечения состояний, связанных с рецептором s1p1 | |
| WO2005063253A1 (fr) | Composition medicinale pour le traitement de symptomes allergiques | |
| US20200206162A1 (en) | Compositions and uses thereof for the treatment of heart failure in domestic animals | |
| JPWO2021067506A5 (fr) | ||
| JP2000355551A (ja) | 医薬組成物 |